RECRUITINGOBSERVATIONAL
Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
Creation of a Multicenter National Registry for Peripartum Cardiomyopathy: a Wide, Multidisciplinary and Translational Perspective to Achieve Personalized Medicine for a Rare Disease in Women
About This Trial
Peripartum cardiomyopathy (PPCM) is a rare, severe and potentially life-threatening disorder of largely unknown etiology and pathophysiology, with unexplained geographical differences and heterogeneous presentation. Investigators hypothesize that a network-based multidisciplinary strategy integrating clinical and molecular phenotyping of PPCM patients might anticipate diagnosis, optimize treatments, and identify novel mechanisms to achieve the unmet goal of personalized medicine.
Who May Be Eligible (Plain English)
Inclusion Criteria
- Development of HF signs or symptoms in the last month of pregnancy or within 5 months of delivery;
- Left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria (LVEF\< 45 %) in the last month of pregnancy or within 5 months of delivery.
Exclusion Criteria
- Presence of any identifiable cause of HF;
- Presence of recognizable heart disease before the last month of pregnancy.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria
* Development of HF signs or symptoms in the last month of pregnancy or within 5 months of delivery;
* Left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria (LVEF\< 45 %) in the last month of pregnancy or within 5 months of delivery.
Exclusion Criteria
* Presence of any identifiable cause of HF;
* Presence of recognizable heart disease before the last month of pregnancy.
Treatments Being Tested
DIAGNOSTIC_TEST
Molecular and genetic screening
Molecular and genetic screening
Locations (1)
Federico II University Hospital
Naples, Italy